'We're pretty cheap at the moment' - Cybin CEO Doug Drysdale
Update: 2024-09-19
Description
Cybin CEO Doug Drysdale talks to Jason Najum about transforming treatment of mental health disorders with psychedelics (0:45 ). CYB003, Phase 2 results for depression, moving into Phase 3 (3:00 ). How deuterated psilocin differentiates Cybin from competiton (10:00 ). IP and patents - critical to ROI (12:45 ). Esketamine and is JNJ's Spravato blazing a trail for psychedelics? (14:15 ) FDA challenges and Lykos lessons (21:20 ). Strong balance sheet will get it through Phase 3 data (25:50 ) Stock consolidation and attracting new buyers (30:35 ).
Episode transcripts
Show Notes:
Imran Khan On Psychedelics - More We Don't Know Than We Do
Psychedelic Stocks: Focus On Their Cash
FDA's MDMA Decision A Setback, But Long-Term Outlook For Psychedelic Stocks Unchanged
De-Risking Psychedelics: Compass Pathways, Cybin And Atai
For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions
Episode transcripts
Show Notes:
Imran Khan On Psychedelics - More We Don't Know Than We Do
Psychedelic Stocks: Focus On Their Cash
FDA's MDMA Decision A Setback, But Long-Term Outlook For Psychedelic Stocks Unchanged
De-Risking Psychedelics: Compass Pathways, Cybin And Atai
For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions
Comments
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
